A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 503 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Selpercatinib August 25, 2022 Young Man’s “Water You Can Eat” Invention for His Grandma with... July 8, 2020 Adjuvant Multiagent Chemotherapy Regimens Associated with OS Benefit Following Resection of... March 11, 2025 ΚΕΝΤΡΙΚΟΥ ΝΕΥΡΙΚΟΥ ΣΥΣΤΗΜΑΤΟΣ March 8, 2019 Load more HOT NEWS How we are working with industry to translate research into real... For Common Form of Bladder Cancer, Chemo Combo Effective Alternative to... 2021 ASCO Annual Meeting Research Round Up: New Research in Gynecologic... ¿Qué son los biosimilares para el tratamiento del cáncer?
